Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study

Manuel J Richter; Jun Wan; Hossein A Ghofrani; Werner Seeger; Henning Gall; Andreas Rieth; Khodr Tello

doi:10.1177/2045894019875342

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study

Pulm Circ. 2019 Sep 11;9(3):2045894019875342. doi: 10.1177/2045894019875342. eCollection 2019 Jul-Sep.

Authors

Manuel J Richter¹, Jun Wan², Hossein A Ghofrani^{1

3

4}, Werner Seeger¹, Henning Gall¹, Andreas Rieth⁵, Khodr Tello¹

Affiliations

¹ Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
² Department of Pulmonary and Critical Care Medicine, National Pulmonary Embolism & Pulmonary Vascular Diseases Research Group, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.
³ Department of Pneumology, Kerckhoff Heart, Rheuma and Thoracic Center, Bad Nauheim, Germany.
⁴ Department of Medicine, Imperial College London, London, UK.
⁵ Department of Cardiology, Kerckhoff Heart, Rheuma and Thoracic Center, Bad Nauheim, Germany.

Abstract

The Breelib™ nebulizer was designed to reduce iloprost inhalation times for patients with pulmonary arterial hypertension (PAH). In 30 patients with PAH, rapid inhalation of iloprost 2.5 µg using Breelib™ caused significant improvements in invasively measured afterload and cardiac index but not echocardiographic right ventricular strain during 30 min post-inhalation.

Keywords: aerosol drug therapy; hemodynamics; prostanoid; pulmonary hypertension; right ventricular function.